[July 28, 2016] |
|
Leading Ohio Critical Access Hospital Adopts Masimo Root® with Radius-7®, Radical-7®, and Patient SafetyNet™ to Create Hospital-Wide Wireless Monitoring and Clinician Notification System
Masimo (NASDAQ:
MASI) announced today that University Hospitals Geneva Medical Center
(UH Geneva), a Critical Access Hospital in Geneva, Ohio, is building a
hospital-wide wireless monitoring and clinician notification system
using Masimo Patient SafetyNet™* in conjunction with Masimo Root®
with Radius-7® and Masimo Radical-7®. UH Geneva is
part of University Hospitals, based in Cleveland, Ohio.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160728005606/en/
Masimo Patient SafetyNet is a supplemental system that enables
information from bedside and tetherless wearable monitors to be
accessible from remote locations and relays alarm notifications to
clinicians. Used with Root, Patient SafetyNet allows hospitals to
automate the transfer of patient vital signs, including temperature and
blood pressure, to patients' medical records, which may help improve
nursing workflows. Root, available with Radical-7 or Radius-7, provides
monitoring of Masimo rainbow SET™ parameters such as oxygen saturation
(SpO2) and total hemoglobin (SpHb), and is expandable to
monitor additional parameters, such as respiration rate from RAM (News - Alert)™
(rainbow® acoustic monitoring). Radius-7 provides continuous
tetherless wearable monitoring of FDA-cleared rainbow SET™ parameters so
that patients can have freedom of movement while being monitored - and
studies have shown that patient mobility is a key factor in more rapid
patient recovery.1,2 Monitoring parameters from Radical-7 or
Radius-7 are sent to Patient SafetyNet through Root, allowing for
hospital-wide remote monitoring and clinician notification.
UH Geneva is part of the University Hospitals system, which employs over
26,000 physicians and employees in Northeast Ohio, and whose flagship
academic medical center, UH Case Medical Center, is the primary
affiliate of Case Western Reserve University School of Medicine. UH
Geneva has been using Masimo SET® pulse oximetry for several
years. Along with implementing such parameters as RAM acoustic
respiration rate, they are now adopting Root with Radius-7, Radical-7,
and Patient SafetyNet to create a hospital-wide wireless monitoring
solution, which will include remote caregiver notification.
Thomas P. Knowles, MHA, RRT, RPSGT, Manager of Respiratory Therapy and
the Center for Advanced Sleep Medicine at UH Geneva, a key stakeholder
in implementing the system, commented, "I've always believed in Masimo's
technology and felt it was important for us to expand our patient
monitoring practices. Patient SafetyNet will provide tremendous
benefits."
"Patient safety is extremely important to us," said Dr. Amitabh Goel,
Chief Medical Officer at UH Geneva Medical Center. "The addition of
Patient SafetyNet, which will work hand-in-hand with Root, Radical-7,
and Radius-7, helps ensure our doctors and nurses always have the data
they need, when they need it. We're also looking forward to integrating
Patient SafetyNet with our EMR system, which will automate many
administrative duties and free up our caregivers to focus on the
enhanced patient experience we strive for."
"UH Geneva provides a compelling example of the standard of care that
more and more community hospitals are adopting," said Joe Kiani, Founder
and CEO of Masimo. "Powerful centralized monitoring and surveillance,
such as those provided by Patient SafetyNet, fueled by industry-leading
rainbow SET™ and innovative devices like Root with Radius-7, are key to
patien monitoring, and it's important, and gratifying, that hospitals
like UH Geneva recognize this. We look forward to deepening our
collaboration with UH Geneva."
@MasimoInnovates |
#Masimo
References
-
Needham D, Korupolu R, Zanni J, Pradhan P, Colantuoni E, Palmer J,
Brower R, Fan E. "Early Physical Medicine and Rehabilitation for
Patients With Acute Respiratory Failure: A Quality Improvement
Project." Archives of Physical Medicine and Rehabilitation.
Vol 91, Issue 4, PP 536-542, April 2010.
-
Ronnenbaum J, Weir J, Hilsabeck T. Earlier mobilization decreases
length of stay in the intensive care unit. J Acute Care Phys Ther.
2012;3(2):204-210.
*The use of the trademark SafetyNet is under license from University
HealthSystem Consortium.
About Masimo Masimo (NASDAQ: MASI) is a global leader in
innovative noninvasive monitoring technologies. Our mission is to
improve patient outcomes and reduce the cost of care by taking
noninvasive monitoring to new sites and applications. In 1995, the
company debuted Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, which has been shown in multiple studies to
significantly reduce false alarms and accurately monitor for true
alarms. Masimo SET® is estimated to be used on more than 100
million patients in leading hospitals and other healthcare settings
around the world. In 2005, Masimo introduced rainbow® Pulse (News - Alert)
CO-Oximetry technology, allowing noninvasive and continuous monitoring
of blood constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
and more recently, Pleth Variability Index (PVI®) and Oxygen
Reserve Index (ORI™), in addition to SpO2, pulse rate, and
perfusion index (PI). In 2014, Masimo introduced Root®, an
intuitive patient monitoring and connectivity platform with the Masimo
Open Connect™ (MOC-9™) interface. Masimo is also taking an active
leadership role in mHealth with products such as the Radius-7™ wearable
patient monitor and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
About University Hospitals Founded in May 1866, University
Hospitals serves the needs of patients through an integrated network of
18 hospitals, more than 40 outpatient health centers and primary care
physician offices in 15 counties throughout Northeast Ohio. At the core
of our $4 billion health system is University Hospitals Case Medical
Center, ranked among America's best hospitals by U.S. News & World
Report. The primary affiliate of Case Western Reserve University School
of Medicine, UH Case Medical Center is home to some of the most
prestigious clinical and research programs in the nation, including
cancer, pediatrics, women's health, orthopedics, radiology,
neuroscience, cardiology and cardiovascular surgery, digestive health,
transplantation and genetics. Its main campus includes UH Rainbow Babies
& Children's Hospital, ranked among the top children's hospitals in the
nation; UH MacDonald Women's Hospital, Ohio's only hospital for women;
and UH Seidman Cancer Center, part of the NCI-designated Case
Comprehensive Cancer Center at Case Western Reserve University. UH is
the second largest employer in Northeast Ohio with 26,000 employees. For
more information, go to www.UHhospitals.org.
Forward-Looking Statements This press release includes
forward-looking statements as defined in Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in
connection with the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Radical-7®,
Root® with Radius-7®, and Patient SafetyNet™.
These forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo Radical-7, Root with
Radius-7, and Patient SafetyNet, contribute to positive clinical
outcomes and patient safety; risks related to our belief that Masimo
noninvasive medical breakthroughs provide cost-effective solutions with
comparable accuracy and unique advantages, including: immediate and
continuous results that enable earlier treatment without causing
invasive trauma in all patients and in every clinical situation; as well
as other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission
("SEC (News - Alert)"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws. -end-
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005606/en/
[ Back To TMCnet.com's Homepage ]
|